ArticleFrontiers in endocrinology2025
Association between triglyceride-glucose index and sarcopenia in patients with chronic kidney disease.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of the triglyceride-glucose index with the risk of sarcopenia: a meta-analysis with clinical implications.BMC endocrine disorders · 2026Pooled it
- Unravelling Sarcopenia in Chronic Kidney Disease: From Pathogenesis to Diagnosis and Therapeutics.Diagnostics (Basel, Switzerland) · 2026Review
- The triglyceride-glucose index in chronic kidney disease: a narrative review.Frontiers in nutrition · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to examine the relationship between the triglyceride-glucose index (TyG) and sarcopenia in patients with chronic kidney disease (CKD). The aim was to gain new insights into preventing and treating sarcopenia in CKD patients. Methods: The study utilized data from two cohorts, including the NHANES 2011-2018 cohort in the United States and the 2018-2023 cohort in China. After applying uniform inclusion and exclusion criteria, 827 patients with CKD in the US cohort and 1,038 patients with CKD in the Chinese cohort were ultimately included in the study. The relationship between the TyG index and sarcopenia was analyzed using logistic regression modeling and multivariate adjustment. The dose-response relationship was also explored using restricted cubic spline (RCS) modeling. Subgroup analyses were also conducted to investigate the potential heterogeneity among different characteristic subgroups. Results: The TyG index was found to be significantly and positively associated with sarcopenia in patients with CKD in both the United States and Chinese cohorts. In the US cohort, the risk of sarcopenia was increased 4.01-fold in the highest TyG quartile group compared with the lowest quartile group (P=0.002). In the Chinese cohort, the corresponding risk was increased 3.25-fold (P<0.001). Furthermore, the RCS analysis corroborated the nonlinear positive association. Subgroup analyses revealed that the correlation between TyG and sarcopenia was more pronounced in patients without diabetes and without metabolic syndrome. Conclusion: The TyG index may serve as a potential biomarker for assessing sarcopenia in CKD patients, thereby supporting the critical role of insulin resistance in developing sarcopenia. Further research is required to elucidate the precise mechanisms by which TyG is associated with sarcopenia and to develop tailored intervention strategies for different patient groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.